Literature DB >> 23648908

Preventing acute exacerbations and hospital admissions in COPD.

Nathaniel Marchetti1, Gerard J Criner2, Richard K Albert3.   

Abstract

COPD is a leading cause of morbidity and mortality worldwide and is now the third leading cause of death in the United States. Acute exacerbations of COPD (AECOPDs) are common events that often lead to hospitalization, and their frequency worsens with disease progression. AECOPDs are associated with worsened quality of life, increased health-care costs, and increased mortality. Accordingly, there is great interest in preventing AECOPDs to improve outcomes. Both pharmacologic and nonpharmacologic interventions alter the frequency of AECOPDs and COPD-related hospitalizations. To examine the best available evidence, we restricted this review to include studies that used randomized controlled designs lasting at least 6 months. Pharmacologic interventions discussed include inhaled corticosteroids, long-acting β-agonists, long-acting antimuscarinic agents, macrolide antibiotics, and phosphodiesterase-4 inhibitors. The nonpharmacologic interventions discussed include lung volume reduction surgery, pulmonary rehabilitation, and disease management programs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648908     DOI: 10.1378/chest.12-1801

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  22 in total

Review 1.  Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).

Authors:  Han Ni; Aung Htet; Soe Moe
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

2.  Identifying Patients With COPD at High Risk of Readmission.

Authors:  Jacob E Simmering; Linnea A Polgreen; Alejandro P Comellas; Joseph E Cavanaugh; Philip M Polgreen
Journal:  Chronic Obstr Pulm Dis       Date:  2016-08-29

3.  Preventing COPD exacerbations: new options for a crucial and growing problem.

Authors:  Jeffrey L Curtis; Carlos H Martinez
Journal:  Fed Pract       Date:  2014-03

4.  Results of a Medicare Bundled Payments for Care Improvement Initiative for Chronic Obstructive Pulmonary Disease Readmissions.

Authors:  Surya P Bhatt; J Michael Wells; Anand S Iyer; deNay P Kirkpatrick; Trisha M Parekh; Lauren T Leach; Erica M Anderson; J Greg Sanders; Jessica K Nichols; Cindy C Blackburn; Mark T Dransfield
Journal:  Ann Am Thorac Soc       Date:  2017-05

5.  Hospitalizations and ED Visits in COPD: A Collision of Socioeconomic Realities with Chronic Comorbid Medical Illnesses.

Authors:  Michael R Jacobs; Abhinav Rastogi; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2016-04-07

6.  Feasibility of Using Daily Home High-Flow Nasal Therapy in COPD Patients Following a Recent COPD Hospitalization.

Authors:  Gerard J Criner; Lii-Yoong H Criner; Sheril A George; Jiji K Thomas; Michael R Jacobs
Journal:  Chronic Obstr Pulm Dis       Date:  2022-01-27

7.  Chronic obstructive pulmonary disease readmissions at minority-serving institutions.

Authors:  Valentin Prieto-Centurion; Hélène A Gussin; Andrew J Rolle; Jerry A Krishnan
Journal:  Ann Am Thorac Soc       Date:  2013-12

8.  Use of a SmartPhone/Tablet-Based Bidirectional Telemedicine Disease Management Program Facilitates Early Detection and Treatment of COPD Exacerbation Symptoms.

Authors:  Heidi S Smith; Andrew J Criner; Dolores Fehrle; Carla L Grabianowski; Michael R Jacobs; Gerard J Criner
Journal:  Telemed J E Health       Date:  2015-10-09       Impact factor: 3.536

9.  Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

Authors:  Han Ni; Soe Moe; Zay Soe; Kay Thi Myint; K Neelakantan Viswanathan
Journal:  Cochrane Database Syst Rev       Date:  2018-12-11

10.  Readmissions Reduction Program: Mortality and Readmissions for Chronic Obstructive Pulmonary Disease.

Authors:  Daniel A Puebla Neira; En Shuo Hsu; Yong-Fang Kuo; Kenneth J Ottenbacher; Gulshan Sharma
Journal:  Am J Respir Crit Care Med       Date:  2021-02-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.